A Pre-Operative Study Evaluating Nivolumab Plus ADI-PEG 20 in Patients With Resectable Hepatocellular Carcinoma
Latest Information Update: 17 Feb 2023
At a glance
- Drugs Nivolumab (Primary) ; Pegargiminase (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Feb 2023 Status changed from recruiting to withdrawn prior to enrolment due to 0 patient accrual.
- 14 Apr 2022 Status changed from not yet recruiting to recruiting.
- 09 Mar 2022 Planned End Date changed from 31 Mar 2022 to 30 Apr 2024.